NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions

June 10, 2014 NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’sCandida vaccine pipeline. These three antigens are in addition to the Company’s agglutinin-like sequence 3 (Als3) antigen used in NDV-3, NovaDigm’s lead vaccine being evaluated in an …